Elan re-explores drug delivery spin-off; Banner Alzheimer's Institute gets $6.5M from NIH;

 @FierceBiotech: Venter: Synthetic cells will revolutionize vax development. News | Follow @FierceBiotech

 @JohnCFierce: I'd be willing to bet $1 that one year from now we'll start seeing the "where-are-all-the-biosimilar-drugs?" stories. Follow @JohnCFierce

> Researcher: New vaccine "could eliminate breast cancer." Story

> With the improved financial environment, Elan is re-exploring the potential spin-out of its drug delivery unit. The developer says that potential investors are more positive about move now then when it was first considered in 2008. Story

> The Banner Alzheimer's Institute has received $6.5 million from the NIH, which will create 100 construction jobs and 34 permanent research jobs in Phoenix. Report

> SynapDx, a provider of diagnostic testing for the early detection of autism, has raised $9 million in Series A funding. Report

> Vaccine maker CSL has recalled its padiatric flu shot in Australia after investigations failed to explain a significant increase in fever and convulsions, according to Bloomberg. News

> The drug industry is watching some of its biggest drugs go off patent, but seems unable to produce new meds to take their place. Forbes' scribe Matthew Herper wonders wonders whether the industry's secrecy is preventing new drug development. Piece

And Finally... Are biotech lab workers exposed to hazardous conditions? Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.